Advertisement
Advertise here Publish your press releases here Sponsor BioPortfolio
Follow us on Twitter Sign up for daily news and research emails Contributors wanted

Pharmasset, Inc. Company Profile

01:46 EDT 20th April 2014 | BioPortfolio

We are a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. Our primary focus is on the development of oral therapeutics for the treatment of human immunodeficiency virus, or HIV, hepatitis B virus, or HBV, and hepatitis C virus, or HCV. Our research and development efforts focus on a class of compounds known as nucleoside analogs, which act to inhibit the natural enzymes required for viral replication.

Location

303-A College Road East
Princeton
New Jersey
08540
United States of America

Contact

Phone: (609) 613-4100
Fax: (609) 613-4150
Email: info@pharmasset.com


News Articles [7 Associated News Articles listed on BioPortfolio]

Comment on Bringing New Rx Drugs to Market in 2014 by Mike Wokasch

I think it is important to also point out that it cost Gilead $11 billion to acquire Pharmasset and thereby secure the rights to Sovaldi. They still had to pay costs associated with completing develo...

Gilead wins US ruling in hepatitis C patent dispute with Idenix

The ruling, announced by Idenix January 29, is the latest setback for Idenix, which is trying to prove that its patents were violated by the biotech company Pharmasset (now part of Gilead). In the lat...

Gilead's Potential Riches Spawns Hepatitis Wars

Gilead's hepatitis C drug, Solvaldi, sales have really taken off. Analysts are predicting megablockbuster status -- with high predictions of as much as $8 B in annual sales by as early as this year. T...

Idenix announces decision by USPTO Patent Trial and Appeal Board in first patent interference

Idenix Pharmaceuticals has announced that the US Patent and Trademark Office (USPTO) Patent Trial and Appeal Board issued a decision in the first patent interference proceeding (No. 105,871) concernin...

Gilead Sciences: Strong Long-Term Growth At A Bargain

ByGaurav S. Sharma:Gilead Sciences (GILD) has been a tremendous performer over the last few years as part of the multi-year biotech bull market. However, it has taken a significant dip in the past few...

Gilead Sciences: Sovaldi Hepatitis C Pill Approved

ByPharma Reports:Last week, the FDA approved Gilead Sciences' (GILD) Sovaldi for hepatitis C. The approval was very much anticipated, nevertheless, since we have developed a deep interest in tracking...

AHF to Ask States to Block Gilead’s $1,000 per Pill Hepatitis Drug From Medicaid Formularies

Gilead is not the original developer of Sovaldi, its new Hepatitis C medication that will cost $84,000 for a 12-week course of treatment; instead, it bought the drug developer, ri...

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [1 Associated Companies listed on BioPortfolio]

Pharmasset, Inc.

We are a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. Our primary focus is on the development of oral therapeut...

More Information about "Pharmasset, Inc." on BioPortfolio

We have published hundreds of Pharmasset, Inc. news stories on BioPortfolio along with dozens of Pharmasset, Inc. Clinical Trials and PubMed Articles about Pharmasset, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Pharmasset, Inc. Companies in our database. You can also find out about relevant Pharmasset, Inc. Drugs and Medications on this site too.

Search BioPortfolio:
Advertisement

Corporate Database Quicklinks



Searches Linking to this Company Record

Advertisement